Clinical Trial Update: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the combination of enzalutamide and cabazitaxel for metastatic castration-resistant prostate cancer; results were posted in December …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• Xtandi (enzalutamide)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-12-23